Point72 Asset Management’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-293,611
Closed -$2.82M 2727
2023
Q4
$2.82M Sell
293,611
-35,257
-11% -$171K 0.01% 1096
2023
Q3
$855K Hold
328,868
﹤0.01% 1373
2023
Q2
$1.54M Hold
328,868
﹤0.01% 1081
2023
Q1
$1.24M Hold
328,868
﹤0.01% 1070
2022
Q4
$1.04M Buy
328,868
+18,800
+6% +$46.8K ﹤0.01% 1040
2022
Q3
$933K Sell
310,068
-18,800
-6% -$46.9K ﹤0.01% 1077
2022
Q2
$819K Sell
328,868
-21,132
-6% -$97.1K ﹤0.01% 1114
2022
Q1
$2.72M Sell
350,000
-698,956
-67% -$5.07M 0.01% 824
2021
Q4
$4.37M Buy
1,048,956
+190,944
+22% +$1.19M 0.02% 701
2021
Q3
$6.79M Sell
858,012
-17,129
-2% -$144K 0.03% 593
2021
Q2
$7.07M Buy
875,141
+125,141
+17% +$1.08M 0.03% 529
2021
Q1
$8.04M Buy
750,000
+200,000
+36% +$2.34M 0.04% 475
2020
Q4
$6.46M Buy
+550,000
New +$6.91M 0.03% 538
2020
Q3
Sell
-60,000
Closed -$1.05M 1136
2020
Q2
$1.05M Buy
+60,000
New +$1.05M 0.01% 669

Other funds holding FUSN

Point72 Asset Management's FUSN Position: Q1 2024 in Review

Point72 Asset Management sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 293,611 shares — an estimated $2.82M sold.

Point72 Asset Management first reported a position in FUSN in Q2 2020 and held it in 14 quarters. The position peaked at $8.04M in Q1 2021. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • Point72 Asset Management reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
  • Point72 Asset Management sold 293,611 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $2.82M.
  • Point72 Asset Management first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 14 quarters.
  • Point72 Asset Management's Fusion Pharmaceuticals Inc. Common Shares position peaked at $8.04M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.